Structure-Based Optimization of Novel Sterol 24-C-Methyltransferase Inhibitors for the Treatment of Candida albicans Infections

• Published in: Journal of medicinal chemistry Vol. 67; no. 11; pp. 9318 - 9341
• Main Authors: Wang, Xue, Jin, Xueyang, Zhao, Fabao, Xu, Zejun, Tan, Wenzhuo, Zhang, Jiaozhen, Xu, Yuliang, Luan, Xiaoyi, Fang, Min, Xie, Zhiyu, Chang, Wenqiang, Lou, Hongxiang
• Format: Journal Article
• Language: English
• Published: WASHINGTON American Chemical Society 13.06.2024; Amer Chemical Soc
• Subjects: Chemistry, Medicinal; Life Sciences & Biomedicine; Pharmacology & Pharmacy; Science & Technology; TARGET; MORPHOGENESIS; METHYLTRANSFERASE; VIRULENCE
• ISSN: 0022-2623; 1520-4804; 1520-4804
• DOI: 10.1021/acs.jmedchem.4c00470

Interfering with sterol biosynthesis is an important strategy for developing safe and effective antifungal drugs. We previously identified compound H55 as an allosteric inhibitor of the fungal-specific C-24 sterol methyltransferase Erg6 for treating Candida albicans infections. Herein, 62 derivatives of H55 were designed and synthesized based on target–ligand interactions to identify more active candidates. Among them, d28 displayed the most potent antivirulence ability (MHIC50 = 0.25 μg/mL) by targeting Erg6, exhibiting an 8-fold increase in potency compared with H55. Moreover, d28 significantly outperformed H55 in inhibiting cell adhesion and biofilm formation, and exhibited minimal cytotoxicity and negligible potential to induce drug resistance. Of note, the coadministration of d28 and other sterol biosynthesis inhibitors, such as tridemorph or terbinafine, demonstrated a strong synergistic antifungal action in vitro and in vivo in a murine skin infection model. These results support the potential application of d28 in the treatment of C. albicans infections.